PSK : 生体の生物活性を修飾するマルチ薬剤

概要

論文の詳細を見る
PSK (protein-bound polysaccharide K) is a biological response modifier, which has been approved and is widely used in Japan. Several randomized controlled trials and meta-analyses very favorably and convincingly evidenced that PSK is effective in immunochemotherapy combined with fluoropyrimidines for treating gastric, colorectal and small cell lung cancer patients. The immunopotentiation of PSK is based on 1) product inhibition or neutralization of immunosuppressive substances associated with surgical invasion or cancer progression, 2) product induction of various cytokines, 3) activation of effector cells such as lymphocytes and natural killer cells, 4) direct action on cancer cells, and other mechanisms reported. In a chemically induced mouse model of inflammatory bowel disease and colorectal carcinogenesis, we recognized that PSK has dual antagonistic effects on inflammation and carcinogenesis. Further studies will help us to elucidate unknown effects of PSK.
福岡歯科大学学会の論文
2006-12-25